B-lymphocyte antigen CD19 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13B-lymphocyte antigen CD19 shows approved-linked disease relevance led by acute lymphoblastic leukemia. 5 more disease programs remain visible in the same review block. 9 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P15391. Start with acute lymphoblastic leukemia, then reuse UniProt P15391 as the stable protein anchor across project notes and exports.
Start with acute lymphoblastic leukemia, then reuse UniProt P15391 as the stable protein anchor across project notes and exports.
B-lymphocyte antigen CD19 shows approved-linked disease relevance led by acute lymphoblastic leukemia. 5 more disease programs remain visible in the same review block. 9 linked drugs remain visible in the same block.
Start review with acute lymphoblastic leukemia because it currently carries approved-linked support. Linked drugs include BLINATUMOMAB, BREXUCABTAGENE AUTOLEUCEL, COLTUXIMAB RAVTANSINE, DENINTUZUMAB MAFODOTIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyB-lymphocyte antigen CD19
Review this target as B-lymphocyte antigen CD19, mapped to UniProt P15391. Sequence length is 556 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats B-lymphocyte antigen CD19 as ChEMBL target CHEMBL3390821, mapped to UniProt P15391. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether B-lymphocyte antigen CD19 is the right protein anchor across sources, using UniProt P15391 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why acute lymphoblastic leukemia is currently framed as approved-linked support. It currently carries 9 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | B-lymphocyte antigen CD19 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P15391 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | B-lymphocyte antigen CD19 |
| UniProt Accession | P15391 |
| Component Type | Protein |
| Sequence Length | 556 aa |
B-lymphocyte antigen CD19
Review this target as B-lymphocyte antigen CD19, mapped to UniProt P15391. Sequence length is 556 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
B-lymphocyte antigen CD19 shows approved-linked disease relevance led by acute lymphoblastic leukemia. 5 more disease programs remain visible in the same review block.
Start review with acute lymphoblastic leukemia because it currently carries approved-linked support. Linked drugs include BLINATUMOMAB, BREXUCABTAGENE AUTOLEUCEL, COLTUXIMAB RAVTANSINE, DENINTUZUMAB MAFODOTIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.